Pen Medicine at the 2023 ASCO Annual Meeting

NEWSWISE — CHICAGO — Researchers from the University of Pennsylvania Abramson Cancer Center and Perelman School of Medicine will discuss the latest advances in clinical cancer research at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago, Illinois. publish data on the progress of follow me on twitter @PennMDForum and @PennCancer for updates.

expert interview

Perelman College of Medicine experts are available to comment on a wide range of topics in cancer science and medicine during on-site meetings or via video calls, phone calls, and emails.

Incoming ASCO Leader from Penn Medicine

ASCO President Elect Lynn M. Schuchter, MD, FASCOThe Madeline and Leonard Abramson Professor of Clinical Oncology and Director of the Tara Miller Melanoma Center will begin his term as ASCO President for the 2023-2024 term following the Annual Meeting. Learn more about her selection to the Association of Top Professionals in Cancer Care.

In addition, Angela DeMichel, M.D., M.Sc.Jill and Alan Miller Breast Cancer Excellence Endowment Chairs will chair the Scientific Programs Committee. Chal Agarwal, MD, MPHLeslie M. Heisler, Lung Cancer Distinguished Associate Professor of Hematology and Oncology, will chair the Communications Committee at the 2024 ASCO Annual Meeting.

news release

Two Penn Medicine Abramson Cancer Center Faculty Receive Top ASCO Award

Please check back for additional news if the embargo is lifted during the conference.

main presentation

Penn Medicine researchers will present clinical trial results in recurrent glioblastoma and metastatic HR+/HER2- breast cancer. The experts will also present studies focused on conversations about serious illness in cancer patients, the impact of Medicaid expansion on clinical trial enrollment, and infertility among female oncologists. Key presentations include:

central nervous system tumor

  • A Phase II Study of Immunotherapy with Fractionated Stereotactic Radiotherapy for Recurrent Glioblastoma (Abstract 2004): In a single-center, multigroup study of patients with recurrent glioblastoma, Stephen Bagley M.D., M.Sc.Assistant professors of hematology oncology and neurosurgery evaluated the immunotherapeutic agents retifanlimab (an anti-PD1 drug) and INCAGN01876 (a GITR agonist) in combination with fractionated stereotactic radiotherapy administered as an immunostimulatory strategy. In the cohort of patients who received concomitant immunotherapy drugs as neoadjuvant therapy before surgery, patients who also received neoadjuvant radiotherapy (cohort B1) compared to patients who received neoadjuvant immunotherapy alone (cohort B2) experienced a clear overall survival benefit compared with Stronger and sustained inflammatory and cell-mediated immune responses in peripheral blood were also seen in cohort B1, supporting preclinical evidence that fractionated stereotactic radiotherapy may help stimulate anti-tumor immune responses. Treatment plan efficacy was not observed in cohort B2 or the other patient group where surgery was not included in the treatment plan (cohort A). Bagley will present the findings in an oral abstract session at S100a on Friday, June 2 at 2:45 pm CT..

breast cancer

  • BRACELET-1 (PrE0113), a phase II study of an oncolytic reovirus in metastatic HR+/HER2- breast cancer (Abstract 1012): This multicenter clinical trial enrolled 48 patients with HR+/HER2- metastatic breast cancer and treated them with chemotherapy alone (cohort 1), pereolep, an oncolytic reovirus designed to attack cancer cells. Patients were randomized to receive combined chemotherapy (cohort 2) or both treatments. with the addition of immunotherapy avelumab (cohort 3).As Clinical Trial Co-PI and Penn Medicine Site PI Dr. Amy ClarkAssistant professor of hematology oncology and colleagues say that early data show a higher response rate with chemotherapy plus pelaleolep compared with chemotherapy alone, with a 6-month progression-free survival, indicating that pelaleolep was found that it increased the T-cell response of His one-third of patients discontinued either pereolep or avelumab because of adverse side effects from treatment. Dr. Clark will present the results at the Dr. Bernard Fischer Annual Clinical Science Symposium on Saturday, June 3 at 1:15 p.m. Central Time at S406..

Equity in Oncology

  • Infertility and Selective Fertility Preservation Survey of Female Medical Oncologists and Residents (Abstract 11001): Dr. Emily McDuffieA radiation oncology resident, she and her colleagues designed a study to learn more about the attitudes of self-proclaimed female oncologists in the United States at all career levels toward family planning and the use of assisted reproductive technology. Physician training often coincides with peak pregnancy, and female physicians are known to have higher infertility rates than the general population. Of the 1,005 female oncologists surveyed, one-third (32%) of them reported experiencing infertility. Among those who experienced infertility, 39% reported having out-of-pocket costs of her $10,000 or more for assisted reproduction. About three-quarters of female primary care physicians (76%) and residents (72%) interested in future fertility preservation were unsure of its feasibility. Dr. McDuffie will present the results at a clinical science symposium session on Saturday, June 3 at 4:30 p.m. Central Time at S100a..

Health service research, quality improvement, care delivery and regulatory policy

  • End-of-Life Expenditure Analysis from the Critical Illness Communication Nudge Study (Abstract 6515): This secondary analysis is JAMA Oncology In January, it discovered that machine learning-powered nudges that facilitate critical illness communication between cancer patients improve end-of-life care.In this follow-up, the lead author Dr. Ravi B. ParikhAn associate professor of medical ethics and health policy and medicine, they found that the intervention reduced spending on health care during the last 180 days of life, largely due to reduced spending on chemotherapy, outpatient care, and other treatments. was also found to decrease. Parikh will present the results in a poster discussion session on Saturday, June 3 at 4:30 pm Central Time at E350..
  • Patient- and Clinician-Driven Strategies for Improving Critical Illness Communication (Abstract 1514): Following the nudge model above to encourage conversations about serious illness, this randomized clinical trial added another layer. It’s a patient message sent electronically prior to a clinic visit that includes her three-question survey designed to prepare patients to discuss oncology and serious illness. team. In a study of 4,450 cancer patients, Samuel Takborian, MD, MScAssistant professors of hematology and oncology found that when both patients and physicians were nudged, they were more likely to have conversations about serious illness than in controls or when only one was nudged. discovered. Takvorian will present the results in a poster discussion session at S102 on Monday, June 5th at 4:30 PM Central Time..
  • Medicaid Expansion and More Black and Hispanic Patients into Cancer Clinical Trials (Abstract 1510)Using anonymized data from 75,700 participants across 1,409 clinical trials and 351 centers, Takvorian et al. We compared clinical trial demographics to determine whether expansion increased the proportion of black and Hispanic patients. Enrolled in an oncology clinical trial. Medicaid expansion alone had no statistically significant impact, but states that mandated Medicaid coverage of routine costs of trial participation significantly increased enrollment of black and/or Hispanic participants. increased to Takvorian will present the results in a poster discussion session at S102 on Monday, June 5th at 4:30 PM Central Time..


Penn Medicine is one of the world’s leading academic medical centers, dedicated to medical education, biomedical research, and related missions of excellence in patient care. Pen medicine consists of: University of Pennsylvania Raymond Perelman and Ruth Perelman School of Medicine (Established in 1765 as the first medical school in Japan) University of Pennsylvania Health Systemtogether forming an $8.6 billion company.

Perelman School of Medicine consistently ranks among the top National Institutes of Health funding sources in the nation, with $494 million awarded in fiscal 2019.

The patient care facilities of the University of Pennsylvania Health System include the University of Pennsylvania Hospital and Penn Presbyterian Medical Center. These are Chester County Hospitals, recognized by US News & World Report as one of the nation’s top “honored” hospitals. Lancaster General Health; Penn Medicine Princeton Health. Other facilities and companies include Good Shepherd Pen Partners, Pen Medicine at Home, Lancaster Behavioral Health Hospital and Princeton House Behavioral Health.

Penn Medicine is powered by over 43,900 talented and dedicated employees. The organization also partners with top community health systems in both southeastern Pennsylvania and southern New Jersey, creating more options for patients wherever they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In 2019, Penn Medicine gave over $583 million to benefit the community.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *